Who should read this?
People newly diagnosed with metastatic prostate cancer, and families trying to understand why treatment today often involves more than hormone therapy alone.
What has changed?
For many years, hormone therapy on its own was the standard treatment. Over the last decade, large clinical trials have shown that adding other treatments early can significantly improve survival for many men.
This evidence has changed how metastatic prostate cancer is treated from the outset.
The modern treatment approach
For most people, treatment now starts with:
• Androgen deprivation therapy (ADT) as the foundation
Often combined with one of the following:
• An androgen receptor pathway inhibitor (ARPI), such as abiraterone, enzalutamide, apalutamide, or darolutamide (the choice depends on individual factors)
And in selected situations:
• Chemotherapy (docetaxel), particularly when disease burden is higher or when rapid cancer control is needed
Sometimes:
• “Triplet therapy” — ADT plus an ARPI plus docetaxel — in carefully selected patients
Why doctors talk about “volume” or “burden”
Not all metastatic prostate cancer behaves the same way.
Some people have only a small number of bone metastases. Others have more extensive bone involvement or spread to organs such as the liver or lungs.
Higher-burden disease is more likely to benefit from treatment intensification early, but decisions are always individual and based on the whole clinical picture.
What this means in real life
Treatment is not “one size fits all.” Instead, it is a planned sequence designed to:
• stabilise the cancer
• control symptoms
• protect long-term health (bones, heart, metabolism)
• preserve future treatment options
Why this matters
Using more effective treatment earlier, when appropriate, can reduce complications and improve long-term outcomes — without “using up” all available options at once.
Key takeaway
Treatment for metastatic castration-sensitive prostate cancer has evolved.
Hormone therapy remains the foundation, but adding other treatments early can improve survival for many men.
The right approach depends on disease burden, overall health, and personal priorities.